Is validation of non-invasive hemodynamic measurement devices actually required?
Department of Cardiology, IRCCS Istituto Auxologico Italiano, Milan, Italy.
Paolo
P
Salvi
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D002227:Carbazoles / Q000627:therapeutic use*; D000077261:Carvedilol; D005260:Female; D006439:Hemodynamics / Q000502:physiology*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology*; D019808:Losartan / Q000627:therapeutic use*; D008297:Male; D011412:Propanolamines / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D002227:Carbazoles; D011412:Propanolamines; D000077261:Carvedilol; D019808:Losartan